Drug Profile
AbGn 107
Alternative Names: AbGn-107Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator AbGenomics Corporation
- Developer AltruBio
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Biliary cancer; Colorectal cancer; Gastric cancer; Pancreatic cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Biliary-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (IV, Infusion)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Biliary-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (IV, Infusion)